

20 Apr 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/04/20/3276770/0/en/novo-nordisk-etavopivat-is-the-first-in-a-new-class-of-drugs-to-meet-both-co-primary-endpoints-in-the-phase-3-hibiscus-trial-substantially-reducing-vaso-occlusive-crisis-events-and.html

11 Dec 2021
// BUSINESSWIRE

04 Nov 2021
// BUSINESSWIRE